Criteria for adjunctive use of hemostats, sealants, glues and adhesion prevention products in surgery

UPDATE: See October 2010 Report #S180, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015.

Although healing of all surgical and procedure-based wounds might be improved through use of adjunctive surgical closure and securement products, it is likely that increased usage of these products will be limited, on economic grounds, to a fraction of procedures. It is realistically estimated that 10%–15% of these procedures would benefit from increased use of newly developed adjunctive surgical closure and securement products. The criteria for our assumptions (based on interviews with clinicians, health care systems and manufacturers) are outlined below, followed by a table on the surgical procedures falling within each category, based on specific procedure attributes.

Criteria for Adjunctive Use of Hemostats, Sealants, Glues and Adhesion Prevention Products in Surgery

Category I: Important and Enabling

Important to prevent excessive bleeding and transfusion, to ensure safe procedure, and to avoid mortality and to avoid complications associated with excessive bleeding and loss of blood.

Category II: Improved Clinical Outcome
Reduces morbidity due to improved procedure, reduced surgery time, and prevention of complications such as fibrosis, post-surgical adhesion formation, and infection (includes adjunct to minimally invasive surgery).

Category III: Cost-Effective and Time-Saving
Immediate reduction in surgical treatment time and follow-up treatments.

Category IV: Aesthetic and Perceived Benefits
Selection is driven by aesthetic and perceived benefits, resulting in one product being favored over a number of medically equivalent treatments.

Source: MedMarket Diligence, LLC report #S175

Surgical Procedures with Potential for the Use of Hemostats, Sealants,
Glues and Adhesion Prevention Products, Worldwide

[table “4” not found /]

Source: MedMarket Diligence report #S175.

Leave a Reply